Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Predicts Technology Will Revolutionize Genomics

Premium

CARLSBAD, Calif.--A new Invitrogen technology that can be used to rapidly clone and express genes will expedite functional validation to keep pace with strides being made in structural genomics and DNA chip-based expressional analysis, according to Invitrogen CEO Lyle Turner. The proprietary technology, amenable to any gene collection, was first tested using the yeast genome. Since October 1997, Invitrogen has cloned 6,000 and expressed 1,000 yeast genes.

Subsequently, Invitrogen launched GeneStorm expression-ready yeast clones, the first in a series of products designed to assist life science researchers design functional validation assays to be applied to drug discovery. The company said it expects to launch its first line of GeneStorm human expression-ready clones this spring.

Filed under

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.